Global Gastrointestinal Stromal Tumors (GIST) Market Size, Share & Trends Analysis Report By Treatment Type (Tyrosine Kinase Inhibitors, Chemotherapy, Immunotherapy, Surgical Intervention), By Line of Therapy (First-Line, Second-Line, Third-Line, Fourth-Line & Beyond, Adjuvant/Neoadjuvant), By Mutation Type (KIT Mutation, PDGFRA Mutation, SDH-Deficient, NF1-Associated, Wild-Type), By Route of Administration (Oral, Intravenous), By End-User (Hospitals & Cancer Centers, Specialty Oncology Clinics, Ambulatory Surgical Centers, Academic & Research Institutes), and By Region (North America, Europe, APAC, Middle East & Africa, LATAM) - Forecasts, 2026-2034.

Table of Contents

1. Introduction

1.1. Market Introduction
1.2. Research Methodology
1.3. Estimation Methodology
1.4. GIST Treatment & Diagnostic Ecosystem Overview
1.5. Market Classification & Scope
1.6. Geographic Scope
1.7. Study Years

2. Market Dynamics

2.1. Drivers: Molecular Testing Expansion, Sequential Targeted Therapy, Rising Diagnosed Incidence
2.2. Restraints: High Cost of Targeted Agents, Reimbursement Constraints, Generic Price Pressure
2.3. Opportunities: Mutation-Specific Therapies, Earlier-Line Treatment Expansion, Resistance-Targeted Drug Development

3. Market Segmentation (2025–2034)

3.1. By Treatment Type
3.2. By Line of Therapy
3.3. By Mutation Type
3.4. By Route of Administration
3.5. By End-User
3.6. By Region

4. Regional Overview

4.1. North America
4.2. Europe
4.3. Asia Pacific
4.4. Middle East & Africa
4.5. Latin America

5. Competitive Analysis

5.1. Market Share Analysis
5.2. Product Portfolio & Pipeline Benchmarking
5.3. Mutation Coverage & Therapeutic Positioning
5.4. Strategic Partnerships, Licensing & Clinical Collaborations

6. Technology & Innovation Trends

6.1. Next-Generation KIT & PDGFRA Inhibitors
6.2. Liquid Biopsy & Circulating Tumor DNA Monitoring
6.3. Next-Generation Sequencing & Molecular Profiling
6.4. Neoadjuvant Targeted Therapy & Multidisciplinary Treatment Planning

7. Regulatory Landscape

7.1. FDA Regulatory Pathways for GIST Therapies
7.2. EMA & European Market Access Framework
7.3. Orphan Drug Designation & Accelerated Approval Pathways
7.4. Global Reimbursement & Health Technology Assessment Policies

8. Market Research Findings & Conclusion

9. Disclaimer